Spain’s largest drugmaker, Almirall (ALM: MC), says that group sales for the first-half of 2011 declined 9.1% year-on-year to 426.5 million euros ($612.7 million), but still showing an improved trend versus the first quarter, when turnover plunged 12.3% to 212.7 million euros.
There was stronger growth in Europe (+3.3%) and a regained impulse in Africa, America and Asia (+3.0%), the company noted, which lifted international sales to 48% of total. Domestic sales (-15.7%), however, were materially affected by the uneven year-on-year comparison. While the first half of 2010 was only partially impacted by the two health care reforms in Spain, the first six months of this year was fully impacted by the price erosion linked to these reforms. Generic competition has also hindered sales performance, especially in the case of Prevencor (atorvastatin), turnover of which plunged45.8% to 22.4 million euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze